Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 8,625 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Trial of The VisAbility Micro Insert System for Presbyopic Patients

NCT02374671
Conditions
Presbyopia
Interventions
VisAbility Micro Insert
Device
Lead sponsor
VisDura, Inc.
Industry
Eligibility
45 Years to 60 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
14
States / cities
Orange, California • San Diego, California • Honolulu, Hawaii + 10 more
Conditions
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
Procedure · Radiation · Other + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 21 more
Completed Phase 3 Interventional Results available

Valproate in Dementia (VALID)

NCT00071721
Conditions
Alzheimer Disease
Interventions
Valproate, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
46
States / cities
Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
Conditions
Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Pembrolizumab, Talimogene Laherparepvec
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Mobile, Alabama • Goodyear, Arizona • Los Angeles, California + 15 more
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Conditions
Leukemia, Myeloid
Interventions
Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more
Conditions
Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms
Interventions
PF-08634404, Bevacizumab, Chemotherapy
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
254
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 173 more
Conditions
Traumatic Brain Injury, Pain
Interventions
Not listed
Lead sponsor
Craig Hospital
Other
Eligibility
16 Years and older
Enrollment
3,805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Englewood, Colorado • Tampa, Florida + 10 more
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Oxaliplatin
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Newark, Delaware • Galesburg, Illinois • Elkhart, Indiana + 6 more
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Completed Phase 4 Interventional Results available

Smoking Cessation Study In Healthy Adolescent Smokers

NCT01312909
Conditions
Smoking Cessation
Interventions
Varenicline 1mg BID, Varenicline 0.5mg BID, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 19 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
56
States / cities
Ozark, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 46 more
Conditions
Prurigo Nodularis
Interventions
Dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Fremont, California • Laguna Hills, California + 18 more
Conditions
Heart Failure, Ventricular Dyssynchrony
Interventions
Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
62
States / cities
Concord, California • Los Angeles, California • Rancho Mirage, California + 46 more
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Interventions
Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
541
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more
Conditions
Lichen Planopilaris
Interventions
Oral Brepocitinib, Placebo
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Conditions
Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Chronic Kidney Disease
Interventions
PRT-201, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 18 more
Conditions
Post-Operative Atrial Fibrillation
Interventions
AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
Device · Drug
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
San Diego, California • Stanford, California • Orlando, Florida + 15 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CC100, Placebos
Drug
Lead sponsor
Chemigen, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Prostate Cancer
Interventions
Plenaxis
Drug
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
60
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
Conditions
Diabetes Mellitus, Type 1
Interventions
otelixizumab infusion plus physician determined standard of care, placebo infusion plus physician determined standard of care
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 58 more
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
ACE-083, ACE-083 or placebo
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 15 more